Connect with us
AstraZeneca and 13 scientific societies signed a document promoting a multidisciplinary approach to cardio-renal-metabolic diseases. The agreement emphasizes early diagnosis, care coordination, research, awareness, screening, equitable...
AstraZeneca is acquiring Belgian biotech EsoBiotec for up to $1 billion to enhance its cancer therapy portfolio. EsoBiotec's innovative ENaBL platform enables rapid, cost-effective cell therapy...
AstraZeneca aims to nearly double its 2023 sales to $80 billion by 2030, focusing on cancer and rare disease treatments. CEO Pascal Soriot highlighted twelve potential...
AstraZeneca and Wivi Vision were awarded the Bioèxit Prize during the Nit event organized by CataloniaBio&HealthTech. AstraZeneca was recognized for establishing its global hub in Barcelona,...
In December 2023, the company reached an agreement to acquire the entire share capital of the Chinese start-up Gracell Biotechnologies for a price that could reach...
The pharma sector faces a setback in sustainability, as AstraZeneca, Novartis, and Amgen, previously included in the Dow Jones Sustainability Index, are omitted in the latest...
Currently, the British multinational does not have any project related to this type of therapy. AstraZeneca tried to reach this market through a negotiation with Moderna, but...
AstraZeneca’s commitment to the Spanish territory can also be seen in the creation of infrastructure since it has allocated a total of €5.5 million for the...
AstraZeneca has agreed to acquire CinCor Pharma in a deal that could exceed $1 billion. CinCor Pharma develops treatments for resistant hypertension and chronic kidney disease,...
AstraZeneca will make a first payment of $200 million and another of $120 million in consideration, for Neogene Therapeutics. AstraZeneca is building a portfolio of cell...